IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management attributes the “recovery” in Scent largely to fixing the fundamentals in R&D—moving from a weaker pipeline to a stronger end-to-end capability (molecules, delivery systems, and “leading-edge” perfumery work). Specifically, they say that 2.5 years ago the R&D pipeline was “not what it should have been,” but today they have a “very strong R&D capability,” with “a great pipeline of molecules as well as delivery systems,” and “leading-edge new Fine Fragrances and Consumer Fragrances.” 1
Fine Fragrance recovery is described as recovery despite ongoing geopolitical volatility. The Q2 quarter outcome was helped by active management: Fine Fragrance finished “up slightly positive” after expecting “mid-single digits” decline into the quarter, with the team “manag[ing] that uncertainty and volatility in the market.” 2
For the rest of the year, management frames the recovery pattern as: Q3 softer, Q4 stronger, because of the 20% year-over-year comp in Q3 and the Middle East impact continuing. 2
Management links Consumer Fragrance performance to execution and share gains—specifically: rebuilding R&D capability and the “go-to-market approach with customers,” while “trying to drive market share gains.” 3
They also emphasize that this segment is currently in a growth normalization phase (good Q2 followed by more normalized rates). 3
While your question focuses on Fine vs Consumer Fragrance, the Scent segment’s recovery is also materially supported by Fragrance Ingredients strength. In Q2, Fragrance Ingredients grew “north of 20%,” and management explains part of this is an easier year-over-year delta versus a prior-year decline (“down 10% or more”). 2 They also add that the team “strategically leveraged the synthetics portfolio” to capture more sales amid macro conditions (supply chain disruptions and higher Brent prices). 2
Importantly for recovery durability, they expect normalization back toward higher-value ingredients later in the year/forward periods. 32
Scent profitability is described as improving alongside recovery: Scent EBITDA grew 5% to $134 million in Q2, driven by “volume growth and productivity gains.” 4
(That matters because it indicates recovery is not purely a price/FX story; it’s tied to operating leverage and operational execution.) 4
Management provides a directional “growth-rate” view for H2:
Interpretation (from the excerpts): Fine Fragrance recovery is not described as a straight-line rebound. Rather, management is managing a known external headwind and expects that the combination of weaker Q3 comps/conditions and stronger Q4 recovery will produce an overall H2 growth improvement. 32
Interpretation (from the excerpts): Consumer Fragrance is described as being in a post-strength normalization phase—i.e., it already improved strongly in Q2, and management expects rates to settle to a lower but still positive low-single-digit trend. 3
Management directly links the 2027 outlook support to the progress made in R&D:
On evolution beyond 2026, they state that the shift they are making—particularly in the broader Scent system including Fragrance Ingredients—will take time, but they expect “as we go into next year and the year after, we believe we’ll have a really strong competitive position.” 3
While this statement mentions Fragrance Ingredients in the surrounding discussion, it is explicitly connected to the same operational rebuild and competitiveness theme (compounds/R&D/market share). 3
Management characterizes innovation and reinvestment as part of a reinforcing loop: they emphasize innovation matters and that investment in R&D is important to maintain competitiveness and enable better growth and margin while continuing reinvestment. 5
They also cite that R&D is in an “8% to 9%” range of sales and must be continually reinvested. 5
They discuss transformation progress as driven by “reinvestment and…step changes” that continue to drive the transformational journey. 6
Separately, they say the Scent leadership has a commitment to being leaders in Scent with Fine Fragrance, Consumer Fragrance, Fragrance Ingredients, and R&D teams working together. 1
Bottom line on 2027 support (based on excerpts): Management’s R&D plan is not framed as a single project, but as a capability buildout already underway—strong pipeline (molecules/delivery systems) 1, leading-edge perfumers producing new offerings 1, sustained R&D intensity (8%–9% of sales) 5, and a reinforcing innovation/go-to-market cycle aimed at creating a stronger competitive position as they move into “next year and the year after” (i.e., supporting 2027). 35
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi